health pharma news today obesity drugs glp-1 How Supply and Demand for Weight Loss is Playing Out in 2026 Dozens of new obesity drugs

It works by triggering the release of certain neurotransmitters in the brain that can decrease appetite

Patients on GLP-1 receptor agonists may have altered gastrointestinal motility, theoretically increasing the risk of aspiration during anesthesia

Therefore, results of observational studies should be verified through the analysis of data from randomized trials

Lack of access often leads patients to switch to less effective alternatives or discontinue treatment entirely. Beyond blood sugar control, Novo Nordisk also states that the Ozempic pill is also approved for reducing the risk of major cardiovascular events, including heart attack, stroke, or death, in adults with type 2 diabetes who are at elevated risk

In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse

People taking higher doses, like 2.4 mg or 7.2 mg of Wegovy, typically lose more weight than those on lower doses of injectable or oral Ozempic